drugset / Trial / NCT04964375
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumor. Preliminary antitumor activity will also be assessed. Investigate the pharmacodynamics (PD) effects and Investigate the metabolites of oral ABSK043
Timeline
- Start
- 2021-08-31
- Primary completion
- 2022-10-23
- Completion
- 2023-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABSK043 | Small molecule | 200 mg | Oral |
| Subject | ABSK043 | Small molecule | 400 mg | Oral |
| Subject | ABSK043 | Small molecule | 800 mg | Oral |